Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Insights From Cencora's Dr Lakesha Farmer: Innovative Biosimilar Adoption Strategies

May 26th 2024

By Skylar Jeremias

Video

Lakesha Farmer, PharmD, MBA, from Cencora discusses innovative pricing and reimbursement models incentivizing biosimilar adoption and competitiveness, including dual pricing strategies and the Mark Cuban Cost Plus Program, while highlighting potential impacts on patient assistance programs.

High Clinical Remission, Treatment Persistence With Adalimumab Biosimilar in Pediatric IBD

May 25th 2024

By Deana Ferreri, PhD

Article

A real-world study of the use of adalimumab biosimilars in pediatric inflammatory bowel disease (IBD) in Sicily found “high rates” of clinical remission and treatment persistence, and no unexpected safety concerns.

The Top 5 Biosimilar Articles for the Week of May 20

May 24th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of May 20, 2024.

Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD

May 23rd 2024

By Skylar Jeremias

Article

Two posters from Digestive Disease Week found that switching patients with inflammatory bowel disease (IBD) from Remicade to an infliximab biosimilar did not impact clinical outcomes, with one study focusing on switches in pediatric patients and the other focusing on patients undergoing multiple switches.

Biosimilars Account for 23% Market Share, With Wide Uptake Disparities Across Molecules

May 22nd 2024

By Skylar Jeremias

Article

In the IQVIA Use of Medicines in the US 2024 report, biosimilars were found to be large contributors to lower drug costs and drivers of market growth; however, these products account for about 23% of the overall biologics market, showing wide variation in uptake across molecules.

DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use

May 21st 2024

By Skylar Jeremias

Article

Posters from Digestive Disease Week (DDW) on the ongoing LIBERTY-CD trial assessing Zymfentra, a subcutaneous infliximab product, compared with intravenous infliximab treatment in Crohn disease show the safety and efficacy of the product, as well as the impact of body mass index (BMI) on clinical outcomes.

FDA Approves First Eylea Biosimilars

May 20th 2024

By Skylar Jeremias

Article

The FDA approved the first 2 biosimilars referencing Eylea (aflibercept)—Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy)—for the treatment of ophthalmic conditions.

BioRationality: FDA Pridefully Declares 50th Biosimilar Approval

May 20th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, congratulates the FDA on approving the 50th biosimilar, noting that there's more work to be done to expand the market.

Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report

May 19th 2024

By Skylar Jeremias

Podcast

The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.

Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD

May 18th 2024

By Deana Ferreri, PhD

Article

A real-world study in Spain on patients with inflammatory bowel disease (IBD) found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.